World Kidney Day marks launch of awareness and screening initiative
Dubai, United Arab Emirates – 14 March 2019: Aster Hospitals has launched an awareness and screening initiative to promote prevention of chronic kidney disease (CKD) through education, awareness and early diagnosis.
50 million people worldwide are now estimated to have kidney diseases from various causes. Chronic kidney disease (CKD) causes at least 2.4 million deaths per year and is now the sixth fastest growing cause of death. Through the campaign, Aster Kidney Care will encourage early screening and management at Aster Hospitals. Members of the public can avail of complimentary screening and detailed analysis through a simple urine test and blood creatinine test at Aster Hospitals' Mankhool or Qusais facilities between March 14, 2019 and April 28, 2019. Prior to screening, registration is required at AsterKidneyCare.ae where participants can also review their test results. This site also provides educational material.
Dr. Manu G Krishnan, Specialist, Nephrology, Aster Hospital Al Qusais said, “Kidney disease usually goes undetected, affecting the body for many years before being diagnosed. Without early treatment, kidney disease can progress to End Stage Renal Disease (ESRD) which is permanent kidney failure and can only be treated with dialysis or a transplant. Awareness and early screening can prevent or halt the progression of kidney disease. Anyone with high blood pressure, diabetes, a family history of kidney failure or a body mass index of 30 is strongly encouraged to get themselves tested. Given the region's high diabetes and hypertension profile, it is important to also manage cardiovascular conditions to avoid complications to reduce one's risk profile and overall disease burden on the healthcare system. Prevention is especially important as in extreme cases, CKD can irreparably impair cognitive function and that even dialysis can't save the patient.”
Aster Hospitals will also be hosting screening sessions at leading companies in Dubai and Sharjah, by facilitating tests on site through a mobile facility. The corporate-site screening will comprise of a risk survey reviewing one's health history, blood pressure check, serum creatinine and random blood sugar, along with a general physician consultation. If indicated, the counselor will refer the participant at risk to a nephrologist for further treatment.